<DOC>
	<DOCNO>NCT00144339</DOCNO>
	<brief_summary>The primary objective trial determine whether daily treatment tiotropium ( Spiriva® , Bromuro de Tiotropio® ) inhalation capsule via HandiHaler® reduces rate decline lung function time patient COPD .</brief_summary>
	<brief_title>Evaluation Long- Term Effects Spiriva Lung Function COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Written inform consent . Male female patient 40 year age old . Smoking history least 10 pack year . Diagnosis COPD post bronchodilator FEV1 le equal 70 % predict normal FEV1 &lt; 70 % FVC stable respiratory medication . Significant disease COPD opinion investigator may put patient risk influence patient ability participate . Myocardial infarction past 6 month . Unstable life threaten arrhythmia past year . Hospitalization NYHA heart failure class III IV past year . Active tuberculosis . Asthma . Pulmonary resection . Malignancy treat radiation chemotherapy past 5 year . Respiratory infection 4 week prior screen . Known hypersensitivity anticholinergic drug component . Known moderate severe renal impairment . Known narrow angle glaucoma . Significant symptomatic BPH bladder neck obstruction . Need oxygen therapy &gt; 12 hr/day . Use oral corticosteroid unstable dos &gt; 10 mg/day .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>